Clinical Remission Rates in Patients With Epithelial Ovarian Cancer Before and After the Onset of the COVID 19 Pandemic in an Integrated Healthcare Delivery System
Patients diagnosed with ovarian cancer achieved similar complete and clinical remission rates before and during the pandemic. Association of the pandemic period with complete remission varied for White vs non-White patients.
Authors
- Matthew Monberg (ORCID: https://orcid.org/0009-0006-7462-4782)
- Chun Chao (ORCID: https://orcid.org/0000-0002-6072-4954)
- Natalie L. Ayoub (ORCID: https://orcid.org/0000-0003-2931-5834)
- Amrita Mukherjee (ORCID: https://orcid.org/0000-0002-2659-6557)
- Melissa Hodeib
- Elizabeth A. Szamreta (ORCID: https://orcid.org/0000-0001-7723-3388)
- Kimberly L. Cannavale (ORCID: https://orcid.org/0000-0003-3892-9686)
- Lanfang Xu
- Alec Gilfillan
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- White Memorial Medical Center (US)
- Kaiser Permanente (US)
- Kaiser Permanente Riverside Medical Center (US)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/cmar.s487894
- Citations
- 2
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- AstraZeneca
- American Society of Clinical Oncology